News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel

News, Analysis, Trends, Management Innovations for
Clinical Laboratories and Pathology Groups

Hosted by Robert Michel
Sign In

More U.S. Medical Laboratories Ready to Step up to ISO 15189 Accreditation

North America’s three ISO 15189 accreditation bodies will be at Lab Quality Confab, along with most of the nation’s ISO-15189 accredited clinical pathology laboratories

In the United States and Canada, acceptance and use of ISO 15189:2007 Medical Laboratories has been limited to a handful of clinical pathology laboratories—except in the Canadian province of Ontario, where, starting almost eight years ago, ISO 15189 became the basis of the province’s mandatory clinical laboratory accreditation program.

But now more pathologists and clinical laboratory managers south of the U.S.–Canadian border are asking a fundamental question: “Is ISO 15189 accreditation an effective way to move my laboratory organization to higher levels of analytical quality while continuously reducing or eliminating errors that affect patient safety and clinical outcomes? More senior medical lab leaders are answering this question with a “yes.”

Clinical Laboratories Turning to ISO 15189

(more…)

LabCorp to Acquire Genzyme’s Genetics Pathology Laboratory Testing Business for $925 Million

Price of 2.5 times revenue makes this a high price for a clinical laboratory


Monday, Laboratory Corporation of America (NYSE: LH) agreed to purchase Genzyme Genetics Corp’s. (NASDAQ: GENZ) fetal genetics and oncology testing division for $925 million in cash. Genzyme has shopped its neo-natal genetic testing business since last year.

LabCorp is paying a purchase price that is 2.5 times Genzyme’s $371 million in annual revenue. This is one of the highest prices paid for a clinical pathology laboratory company since Quest Diagnostics Incorporated (NYSE: DGX), paid about 2.5 times revenue for Ameripath, Inc. in March 2007. In that transaction, Quest Diagnostics paid about $2 billion for Ameripath, which had annual revenues approaching $800 million at the time of sale.

(more…)

;